Association Between Body Mass Index and HFNC Therapy Success

Clínica del country303 enrolled

Overview

Patients over 18 years of age who are admitted to the Intermediate Care Unit of the Clinica del Country and the Clinica la Colina, with symptoms suggestive of severe pneumonia secondary to COVID-19 infection and acute hypoxemic respiratory failure. The primary outcome will be to determine the relationship between body mass index and high-flow cannula therapy success defined as: No need for mechanical ventilation.

All adult patients over 18 years of age admitted to the intermediate care service of the participating center with suspected SARS-CoV-2 pneumonia will be considered as potential candidates for the study. The medical records of patients in our cohort who require high-flow cannula therapy and who met all the inclusion criteria and none of the exclusion criteria will be reviewed.All data will be processed and analyzed using the SPSS 26 software once the study is completed. study sample

Study Type

OBSERVATIONAL

Enrollment

303

Conditions

Covid19 Obesity Overweight Pneumonia, Viral

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients over 18 years of age. 2. Diagnosis of severe pneumonia secondary to COVID-19 infection and acute respiratory distress syndrome, defined by upper and lower respiratory symptoms plus positive C-reactive protein test for COVID-19. 3. Patient admission to the Clinical del Country and Clinica de la Colina intermediate care units. 4. Oxygen therapy by high-flow system (high-flow cannula) requirement. 5. Anthropometric data availability upon admission to our facilities. Exclusion Criteria: 1. Patients with a survival expectancy of less than 12 months according to the Charlson scale categorization or patients with oncological pathology. 2. Patients under 18 years of age. 3. Pregnant women. 4. Patients with cardiogenic pulmonary edema. 5. History of chronic liver disease or cirrhosis Child - Pugh C. 6. Patients with contraindications to high-flow cannula therapy initiation. 7. Patients with respiratory, hemodynamic and neurological indications that contraindicate HFNC initiation.

Locations (1)

Clínica del Country.

Bogotá, Colombia

Outcomes

Primary Outcomes

Primary outcome

To determine the relationship between body mass index "BMI" calculated by kg / m2 (BMI was classified in the following categories: normal weight: 18.5-24.9 kg / m2, overweight: 25-29.9 kg / m2, and obesity: ≥ 30 kg / m2) and high-flow cannula therapy success defined as: No need for mechanical ventilation.

Time frame: 1 year.

Secondary Outcomes

Demographic and laboratory characteristics

Describe the clinical, demographic and laboratory characteristics in a population of 303 patients in Bogotá, Colombia with severe pneumonia defined by ATS criteria (confusion, urea \>7 mmol/L, respiratory rate ≥30 min-1, low blood pressure, and age ≥65 years) score except age, arterial oxygen pressure/fraction inspired oxygen (PaO2/FiO2) ≤250 mmHg, multilobar infiltrates, leucopenia, thrombocytopenia, and hypothermia.) secondary to COVID 19 infection (positive C-Reactive protein) and acute hypoxemic respiratory failure defined by a PaFio2 \< 300, in the intermediate care service of the Clínica del Country and Clínica La Colina, between March 2020 and March 2021.

Time frame: 1 year

Body mass index as a predictor

Evaluate the body mass index as a predictor of success in high-flow cannula therapy.

Time frame: 1 year

Body mass index and HFNC success

Evaluate the relationship between body mass index and high-flow nasal cannula therapy success.

Time frame: 1 year

Mortality

Describe the mortality of patients with high-flow cannula therapy in our medical facilities.

Time frame: 1 year

Hospital stay.

The relationship between hospital stay (days) and body mass index in our patients' cohort will be evaluated.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.